Skip to main content

Arch Biopartners Inc(ARCH-X)
TSX Venture

Today's Change
Delayed Last Update

Stocks in play: Arch Biopartners Inc.

Baystreet - Fri Sep 22, 2023

Announced that it has submitted applications to the Ministry of Health (MoH) and local Ethics Committee in Turkey to obtain permission to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver. Arch Biopartners Inc. shares V.ARCH are trading unchanged at $1.45.

Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.